Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAC trial in early breast cancer
ACTRN12606000527561Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 1998
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Arimidex monotherapy, Nolvadex monotherapy and Arimidex + Nolvadex combination (3 arms). Primary endpoints: Time to recurrence of breast cancer and Safety and side effects. Started Apr 1998; status: completed.
02
Drugs
anastrozoletamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000527561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000527561.